H Yki-Jarvinen - New England Journal of Medicine, 2004 - content.nejm.org Insulin resistance both precedes and predicts type 2 diabetes mellitus. 1
Although exercise and weight loss ameliorate insulin resistance and may in some
cases prevent or delay onset of the disease, 2 therapy that combats insulin ... Cited by 838 - Related articles - BL Direct - All 6 versions
- ►shouxi.net B Staels, JC Fruchart - Diabetes, 2005 - Am Diabetes Assoc Peroxisome proliferator–activated receptors (PPARs) play key roles in the
regulation of energy homeostasis and inflammation, and agonists of PPARα and
-γ are currently used therapeutically. Fibrates, first used in the 1970s ... Cited by 265 - Related articles - BL Direct - All 10 versions
- ►ucsf.edu [PDF] GA Francis, E Fayard, F Picard, J Auwerx - Annual review of physiology, 2003 - Annual Reviews ▪ Abstract The metabolic nuclear receptors act as metabolic and toxicological
sensors, enabling the organism to quickly adapt to environmental changes by
inducing the appropriate metabolic genes and pathways. Ligands for these ... Cited by 257 - Related articles - BL Direct - All 7 versions
- ►endojournals.org H Bays, L Mandarino, RA DeFronzo - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance in liver
and muscle and impaired insulin secretion. Considerable evidence also implicates
deranged adipocyte metabolism and altered fat topography in the ... Cited by 245 - Related articles - All 4 versions
- ►nih.gov RK Semple, VKK Chatterjee, SO'Rahilly - Journal of Clinical Investigation, 2006 - Am Soc Clin Investig The nuclear receptor family of PPARs was named for the ability of the original
member to induce hepatic peroxisome proliferation in mice in response to
xenobiotic stimuli. However, studies on the action and structure of the 3 ... Cited by 237 - Related articles - BL Direct - All 10 versions
E Chiquette, G Ramirez, R DeFronzo - Archives of internal medicine, 2004 - archinte.highwire.org You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 197 - Related articles - BL Direct - All 6 versions
- ►ahajournals.org MR Langenfeld, T Forst, C Hohberg, P Kann, G … - Circulation, 2005 - Am Heart Assoc Methods and Results— We compared the effects of pioglitazone-based therapy (45
mg/d) and glimepiride-based treatment (2.7±1.6 mg/d) for 12 and 24 weeks on
metabolic control (HbA 1c ), insulin resistance (homeostasis model ... Cited by 186 - Related articles - All 14 versions
M Bajaj, S Suraamornkul, T Pratipanawatr, LJ … - Diabetes, 2003 - Am Diabetes Assoc The effect of pioglitazone on splanchnic glucose uptake (SGU), endogenous
glucose production (EGP), and hepatic fat content was studied in 14 type 2
diabetic patients (age 50 ± 2 years, BMI 29.4 ± 1.1 kg/m 2 , HbA 1c 7.8 ... Cited by 165 - Related articles - BL Direct - All 4 versions
- ►ahajournals.org N Varo, D Vicent, P Libby, R Nuzzo, AL Calle … - Circulation, 2003 - Am Heart Assoc Methods and Results— Subjects with type 1 (n=49) or type 2 diabetes (n=48) had
higher (P<0.001) sCD40L plasma levels (6.56±3.27 and 6.67±2.90 ng/mL,
respectively) compared with age-matched control groups (1.40±2.21 and ... Cited by 154 - Related articles - BL Direct - All 8 versions
